It is very uncertain whether dopamine agonist changes any other adverse events compared with placebo/no intervention (very low certainty).
Any dopamine agonist showed no clear difference in adverse events as N of participants with at least one adverse event compared with placebo (moderate certainty).
It is very uncertain whether dopamine agonist plus co‐intervention changes any other adverse events compared with co‐intervention (very low certainty).
The review found no eligible studies for this question.
Summary of findings: dopamine agonists leads to higher number of dropouts due to adverse events compared with placebo (high certainty).
Summary of findings: dopamine agonists probably leads to higher number of drop outs due to adverse events compared with levodopa (moderate certainty).
Summary of findings: dopamine agonists showed no clear difference in number of patients experiencing adverse events compared with levodopa (moderate certainty).
Prophylactic dopamine antagonist antiemetic medications showed no clear difference in adverse events compared with placebo (low certainty).